Thermo Fisher Scientific (TMO) stock price, revenue, and financials

Thermo Fisher Scientific market cap is $206.1 b, and annual revenue was $32.22 b in FY 2020

View Company

+6.47(+1.23%)

$206.1 B

TMO Mkt cap, 22-Jul-2021

$32.2 B

Thermo Fisher Scientific Revenue FY, 2020

Thermo Fisher Scientific Revenue growth (FY, 2019 - FY, 2020), %26%

Thermo Fisher Scientific Gross profit (FY, 2020)16.5 B

Thermo Fisher Scientific Gross profit margin (FY, 2020), %51.2%

Thermo Fisher Scientific Net income (FY, 2020)6.4 B

Thermo Fisher Scientific EBIT (FY, 2020)7.8 B

Thermo Fisher Scientific Cash, 31-Dec-202010.3 B

Thermo Fisher Scientific EV217.6 B

Thermo Fisher Scientific Revenue

Thermo Fisher Scientific revenue was $32.22 b in FY, 2020 which is a 26.1% year over year increase from the previous period.

Embed Graph

Thermo Fisher Scientific Revenue Breakdown

Embed Graph

Thermo Fisher Scientific revenue breakdown by business segment: 35.1% from Laboratory Products and Services, 15.3% from Specialty Diagnostics, 14.7% from Analytical Instruments and 34.9% from Life Sciences Solutions

Thermo Fisher Scientific revenue breakdown by geographic segment: 8.7% from China, 51.0% from United States and 40.3% from Other

Annual

USD	FY, 2018	FY, 2019	FY, 2020
Revenue	24.4b	25.5b	32.2b
Revenue growth, %	16%	5%	26%
Cost of goods sold	13.5b	14.2b	15.7b
Gross profit	10.9b	11.3b	16.5b
Gross profit Margin, %	45%	44%	51%
R&D expense	967.0m	1.0b	1.2b
General and administrative expense	6.1b	6.1b	6.9b
Operating expense total	10.9b	7.1b	8.1b
EBIT	3.8b	4.6b	7.8b
EBIT margin, %	16%	18%	24%
Interest expense		676.0m	553.0m
Interest income		224.0m	65.0m
Pre tax profit	3.3b	4.1b	7.2b
Income tax expense	324.0m	374.0m	850.0m
Net Income	2.9b	3.7b	6.4b
EPS	7.2	9.2	16.0

Quarterly

USD	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020
Revenue	5.9b	6.1b	5.9b	6.1b	6.3b	6.3b	6.2b	6.9b	8.5b
Cost of goods sold	3.3b	3.3b	3.3b	2.4b	3.5b	3.5b	3.5b	3.4b	4.2b
Gross profit	2.6b	2.7b	2.6b	3.7b	2.8b	2.8b	2.7b	3.5b	4.3b
Gross profit Margin, %	44%	45%	44%	61%	45%	44%	44%	51%	51%
R&D expense	234.0m	242.0m	240.0m	248.0m	246.0m	247.0m	245.0m	264.0m	296.0m
General and administrative expense	1.5b	1.5b	1.5b	1.5b	1.6b	1.5b	1.6b	1.4b	1.6b
Operating expense total	1.8b	1.8b	1.7b	2.8b	1.3b	1.8b	1.8b	2.1b	1.9b
EBIT	786.0m	937.0m	912.0m	920.0m	1.5b	946.0m	906.0m	1.4b	2.4b
EBIT margin, %	13%	15%	15%	15%	24%	15%	15%	20%	28%
Interest expense							126.0m	137.0m	144.0m
Interest income							36.0m	8.0m	9.0m
Pre tax profit	634.0m	806.0m	810.0m	817.0m	1.4b	822.0m	828.0m	1.3b	2.3b
Income tax expense	55.0m	54.0m	101.0m	2.0m	274.0m	62.0m	40.0m	97.0m	319.0m
Net Income	579.0m	752.0m	709.0m	815.0m	1.1b	760.0m	788.0m	1.2b	1.9b
EPS	1.4	1.9	1.8	2.0	2.8	1.9	2.0	2.9	4.8

Annual

USD	FY, 2018	FY, 2019	FY, 2020
Cash	2.1b	2.4b	10.3b
Accounts Receivable	4.1b	4.3b	5.7b
Inventories	3.0b	3.4b	4.0b
Current Assets	10.6b	11.9b	22.0b
PP&E	4.2b	4.7b	5.9b
Goodwill	25.3b	25.7b	26.0b
Total Assets	56.2b	58.4b	69.1b
Accounts Payable	1.6b	1.9b	2.2b
Short-term debt	1.3b	676.0m	2.6b
Current Liabilities	6.1b	6.2b	10.3b
Long-term debt	17.7b	17.1b	19.1b
Non-Current Liabilities	22.5b	22.5b
Total Debt	19.0b	17.8b	21.7b
Total Liabilities	28.6b	28.7b
Common Stock	432.0m	434.0m	437.0m
Additional Paid-in Capital	14.6b	15.1b	15.6b
Retained Earnings	18.7b	22.1b	28.1b
Total Equity	27.6b	29.7b	34.5b
Debt to Equity Ratio	0.7 x	0.6 x	0.6 x
Debt to Assets Ratio	0.3 x	0.3 x	0.3 x
Financial Leverage	2 x	2 x	2 x

Quarterly

USD	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020
Cash	950.0m	937.0m	1.1b	1.1b	2.3b	1.3b	3.0b	5.8b	7.5b
Accounts Receivable	4.0b	3.9b	3.9b	4.2b	4.1b	4.4b	4.5b	4.5b	5.2b
Inventories	2.9b	2.9b	3.0b	3.1b	3.2b	3.3b	3.5b	3.6b	3.8b
Current Assets	9.6b	9.5b	9.6b	9.9b	11.2b	10.5b	12.7b	15.8b	18.2b
PP&E	4.1b	4.0b	4.0b	4.2b	4.4b	4.4b	4.7b	4.9b	5.2b
Goodwill	25.4b	25.1b	25.1b	25.2b	25.8b	25.6b	25.6b	25.7b	25.8b
Total Assets	56.6b	55.4b	55.1b	55.6b	58.0b	56.7b	58.7b	61.6b	64.1b
Accounts Payable	1.4b	1.4b	1.3b	1.5b	1.4b	1.7b	1.6b	1.4b	1.7b
Short-term debt	2.8b	1.7b	1.0b	1.3b	2.4b	661.0m	738.0m	675.0m	2.0m
Current Liabilities	7.1b	6.0b	5.2b	5.9b	7.5b	5.8b	5.5b	6.0b	6.2b
Long-term debt	18.1b	17.7b	17.8b	16.8b	16.7b	16.4b	19.2b	20.6b	21.1b
Non-Current Liabilities	23.4b	23.0b	23.0b	22.0b	21.7b	21.5b	24.6b	25.7b	26.0b
Total Debt	20.9b	19.4b	18.8b	18.1b	19.0b	17.1b	20.0b	21.3b	21.1b
Total Liabilities	30.5b	29.0b	28.2b	27.9b	29.2b	27.4b	30.1b	31.7b	32.2b
Common Stock	429.0m	430.0m	431.0m	433.0m	433.0m	434.0m	435.0m	436.0m	437.0m
Additional Paid-in Capital	14.3b	14.4b	14.5b	14.8b	14.9b	15.0b	15.2b	15.3b	15.5b
Retained Earnings	16.5b	17.2b	17.9b	19.4b	20.5b	21.2b	22.8b	23.9b	25.7b
Total Equity	26.1b	26.4b	26.9b	27.7b	28.7b	29.4b	28.6b	29.9b	31.8b
Debt to Equity Ratio	0.8 x	0.7 x	0.7 x	0.7 x	0.7 x	0.6 x	0.7 x	0.7 x	0.7 x
Debt to Assets Ratio	0.4 x	0.4 x	0.3 x	0.3 x	0.3 x	0.3 x	0.3 x	0.3 x	0.3 x
Financial Leverage	2.2 x	2.1 x	2 x	2 x	2 x	1.9 x	2.1 x	2.1 x	2 x

Annual

USD	FY, 2018	FY, 2019	FY, 2020
Net Income	2.9b	3.7b	6.4b
Depreciation and Amortization	2.3b	2.3b	2.3b
Accounts Receivable	(366.0m)	(225.0m)	(1.3b)
Inventories	(324.0m)	(458.0m)	(508.0m)
Accounts Payable	201.0m	266.0m	59.0m
Cash From Operating Activities	4.5b	5.0b	8.3b
Purchases of PP&E	(758.0m)	(926.0m)	(1.5b)
Cash From Investing Activities	(1.3b)	(1.5b)	(1.5b)
Long-term Borrowings	(2.1b)	(6.4b)	(1.1b)
Dividends Paid	(266.0m)	(297.0m)	(337.0m)
Cash From Financing Activities	(2.2b)	(3.1b)	959.0m
Net Change in Cash	756.0m	305.0m	7.9b

Quarterly

USD	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020
Net Income	579.0m	1.3b	2.0b	815.0m	1.9b	2.7b	788.0m	1.9b	3.9b
Depreciation and Amortization	575.0m	1.1b	1.7b	555.0m	1.1b	1.7b	574.0m	1.1b	1.7b
Accounts Receivable	(71.0m)	(97.0m)	(64.0m)	(29.0m)	5.0m	(321.0m)	(218.0m)	(195.0m)	(858.0m)
Inventories	(124.0m)	(195.0m)	(333.0m)	(140.0m)	(273.0m)	(449.0m)	(141.0m)	(309.0m)	(427.0m)
Accounts Payable	(94.0m)	(20.0m)	(45.0m)	(129.0m)	(202.0m)	70.0m	(241.0m)	(497.0m)	(220.0m)
Cash From Operating Activities	78.0m	1.5b	2.7b	649.0m	1.9b	3.1b	356.0m	2.2b	5.0b
Purchases of PP&E	(118.0m)	(301.0m)	(474.0m)	(201.0m)	(421.0m)	(637.0m)	(253.0m)	(522.0m)	(888.0m)
Cash From Investing Activities	(179.0m)	(364.0m)	(532.0m)	(181.0m)	(950.0m)	(1.1b)	(260.0m)	(519.0m)	(884.0m)
Long-term Borrowings	(1.6b)	(4.0b)	(5.9b)	(1.0m)	(3.0m)	(1.7b)	(1.0m)	(389.0m)	(712.0m)
Dividends Paid	(60.0m)	(129.0m)	(198.0m)	(68.0m)	(144.0m)	(221.0m)	(76.0m)	(163.0m)	(250.0m)
Cash From Financing Activities	(342.0m)	(1.3b)	(2.2b)	(1.4b)	(735.0m)	(2.6b)	619.0m	1.8b	1.0b
Net Change in Cash	(386.0m)	(405.0m)	(250.0m)	(989.0m)	197.0m	(812.0m)	588.0m	3.4b	5.1b

USD	Q1, 2018
Debt/Equity	0.8 x
Debt/Assets	0.4 x
Financial Leverage	2.2 x

Thermo Fisher Scientific's Customers was reported to be 400 k in FY, 2020. Thermo Fisher Scientific's Backlog was reported to be $7.8b in FY, 2019.

	FY, 2017	FY, 2018	FY, 2019	FY, 2020
Backlog	$4.46 b	$5.09 b	$7.77 b
Backlog (Analytical Instruments)	$2.05 b	$2.24 b	$2.2 b
Backlog (Laboratory Products and Services)	$1.68 b	$2.06 b	$4.58 b
Backlog (Life Sciences Solutions)	$594 m	$647 m	$893 m
Backlog (Specialty Diagnostics)	$158 m	$187 m	$172 m
Customers	400 k	400 k	400 k	400 k
Remaining Performance Obligations				$12.81 b